Double immune attack: new combo therapy targets Hard-to-Treat cancers
NCT ID NCT03030378
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This early-phase trial is testing a combination of two immunotherapy drugs—pembrolizumab and recombinant interleukin-12—in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if the combination can help the immune system fight the cancer better than pembrolizumab alone. The study focuses on safety and tumor response, not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Emory Saint Joseph's Hospital
Atlanta, Georgia, 30342, United States
-
Emory University Hospital Midtown
Atlanta, Georgia, 30308, United States
-
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Siteman Cancer Center at Christian Hospital
St Louis, Missouri, 63136, United States
-
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri, 63376, United States
-
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri, 63141, United States
-
Siteman Cancer Center-South County
St Louis, Missouri, 63129, United States
-
Smilow Cancer Center/Yale-New Haven Hospital
New Haven, Connecticut, 06510, United States
-
UCHealth University of Colorado Hospital
Aurora, Colorado, 80045, United States
-
UCSF Medical Center-Mount Zion
San Francisco, California, 94115, United States
-
UF Health Cancer Institute - Gainesville
Gainesville, Florida, 32610, United States
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
-
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
-
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, 52242, United States
-
University of Texas Health Science Center at San Antonio
San Antonio, Texas, 78229, United States
-
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, 23298, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
-
Yale University
New Haven, Connecticut, 06520, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can a Tumor's DNA guide better cancer care for kids?
- Can a new PET tracer reveal a key cancer target?
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a new tracer light up cancer growth?
- Can a Dual-Pronged antibody outsmart advanced cancers?